Complementary strategies to be used in conjunction with animal models for multiple sclerosis drug discovery: adapting preclinical validation of drug candidates to the need of remyelinating strategies.
Fiche publication
Date publication
juillet 2024
Journal
Expert opinion on drug discovery
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BAGNARD Dominique
Tous les auteurs :
Charmarke-Askar I, Spenlé C, Bagnard D
Lien Pubmed
Résumé
The quest for novel MS therapies focuses on promoting remyelination and neuroprotection, necessitating innovative drug design paradigms and robust preclinical validation methods to ensure efficient clinical translation. The complexity of new drugs action mechanisms is strengthening the need for solid biological validation attempting to address all possible pitfalls and biases precluding access to efficient and safe drugs.
Mots clés
Multiple sclerosis, drug design, drug screening, in vitro models, in vivo models, preclinical validation
Référence
Expert Opin Drug Discov. 2024 07 22;:1-10